CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation

Gao, J; Wang, ZY; Jiang, WQ; Zhang, YN; Meng, Z; Niu, YL; Sheng, Z; Chen, C; Liu, XJ; Chen, X; Liu, CJ; Jia, KR; Zhang, C; Liao, HY; Jung, J; Sung, E; Chung, H; Zhang, JWZ; Zhu, AX; Shen, L

Shen, L (通讯作者)，SIP LifeLink Oncol Res Inst, Suzhou, Peoples R China.;Zhu, AX (通讯作者)，I Mab Biopharma, Shanghai, Peoples R China.;Shen, L (通讯作者)，Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China.;Zhang, JWZ (通讯作者)，I Mab Biopharma, Gaithersburg, MD 20878 USA.

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023; 11 (6):

Abstract

BackgroundClaudin18.2 (CLDN18.2) is a tight junction protein that has been identified as a clinically proven target in gastric cancer. Stimulation of ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索